NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Price Target & More

$10.19 -0.30 (-2.86 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$10.49
Today's Range$10.16 - $10.50
52-Week Range$2.69 - $15.00
Volume164,026 shs
Average Volume426,434 shs
Market Capitalization$557.01 million
P/E Ratio-2.87
Dividend YieldN/A
Beta2.34

About Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company's preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Debt-to-Equity RatioN/A
Current Ratio7.12%
Quick Ratio7.12%

Price-To-Earnings

Trailing P/E Ratio-2.87
Forward P/E Ratio-8.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.28 million
Price / Sales231.38
Cash FlowN/A
Price / CashN/A
Book Value$1.96 per share
Price / Book5.20

Profitability

EPS (Most Recent Fiscal Year)($3.66)
Net Income$-60,040,000.00
Net Margins-2,637.15%
Return on Equity-171.81%
Return on Assets-71.11%

Miscellaneous

Employees44
Outstanding Shares51,770,000

How to Become a New Pot Stock Millionaire

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals (NASDAQ:DRNA) posted its earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.65) by $0.25. The biopharmaceutical company earned $1.40 million during the quarter, compared to analyst estimates of $1.45 million. Dicerna Pharmaceuticals had a negative net margin of 2,637.15% and a negative return on equity of 171.81%. The company's revenue was up 976.9% compared to the same quarter last year. View Dicerna Pharmaceuticals' Earnings History.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

What price target have analysts set for DRNA?

7 brokerages have issued twelve-month target prices for Dicerna Pharmaceuticals' shares. Their predictions range from $10.00 to $17.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $13.20 in the next year. View Analyst Ratings for Dicerna Pharmaceuticals.

What are Wall Street analysts saying about Dicerna Pharmaceuticals stock?

Here are some recent quotes from research analysts about Dicerna Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (2/9/2018)
  • 2. Cowen Inc analysts commented, "DRNA reported 1Q17 results today." (5/9/2017)

Who are some of Dicerna Pharmaceuticals' key competitors?

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas M. Fambrough III, Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 49)
  • Mr. John B. Green CPA, Chief Financial Officer (Age 64)
  • Dr. Bob D. Brown Ph.D., Chief Scientific Officer and Sr. VP (Age 53)
  • Dr. Mark Behlke M.D., Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Prof. John J. Rossi Ph.D., Co-Founder and Chairman of Scientific Advisory Board (Age 71)

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

Press coverage about DRNA stock has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 44.97 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include RA CAPITAL MANAGEMENT, LLC (8.60%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $10.19.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $557.01 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (DRNA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dicerna Pharmaceuticals (NASDAQ:DRNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Dicerna Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.20, suggesting that the stock has a possible upside of 29.54%. The high price target for DRNA is $17.00 and the low price target for DRNA is $10.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.862.672.60
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.20$12.20$8.75$5.3333
Price Target Upside: 29.54% upside9.63% downside0.91% downside63.60% upside

Dicerna Pharmaceuticals (NASDAQ:DRNA) Consensus Price Target History

Price Target History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ:DRNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2018B. RileyInitiated CoverageNeutral$10.00HighView Rating Details
3/23/2018HC WainwrightDowngradeBuy -> Neutral$12.00HighView Rating Details
3/9/2018Chardan CapitalInitiated CoverageNeutral -> NeutralHighView Rating Details
3/9/2018Stifel NicolausBoost Price TargetBuy -> Buy$10.00 -> $17.00HighView Rating Details
2/5/2018SunTrust BanksInitiated CoverageBuy$13.00MediumView Rating Details
1/16/2018Evercore ISIInitiated CoverageOutperform -> Outperform$14.00MediumView Rating Details
5/9/2017CowenReiterated RatingBuyHighView Rating Details
4/2/2017Jefferies GroupReiterated RatingBuy$8.00 -> $7.00LowView Rating Details
2/1/2017Leerink SwannReiterated RatingMkt PerformN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earnings History and Estimates Chart

Earnings by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.75)($0.58)($0.67)
Q2 20182($0.75)($0.59)($0.67)
Q3 20182($0.74)($0.48)($0.61)
Q4 20182($0.46)($0.40)($0.43)

Dicerna Pharmaceuticals (NASDAQ DRNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.87)N/AView Earnings Details
3/8/2018Q4 2017($0.65)($0.90)$1.45 million$1.40 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.70)($0.92)$0.47 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.61)($1.15)$0.08 million$0.25 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.65)($0.68)$0.08 million$0.13 millionViewListenView Earnings Details
3/30/2017Q4 2016($0.73)($0.68)$0.13 millionViewN/AView Earnings Details
11/7/2016Q316($0.87)($0.68)$162.00 millionViewListenView Earnings Details
8/4/2016Q216($0.84)($0.75)ViewN/AView Earnings Details
5/9/2016Q116($0.86)($0.76)ViewN/AView Earnings Details
3/10/2016Q415($0.84)($0.76)$2.50 millionViewListenView Earnings Details
11/10/2015Q315($0.84)($0.82)ViewListenView Earnings Details
8/6/2015Q215($0.78)($0.86)$0.18 millionViewN/AView Earnings Details
5/11/2015Q1($0.7270)($0.79)$600.00 millionViewListenView Earnings Details
3/12/2015Q414($0.57)($0.63)$1.45 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.63)($0.63)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.42)($0.64)ViewN/AView Earnings Details
5/13/2014Q114($0.52)($0.76)ViewN/AView Earnings Details
3/27/2014($0.62)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Dicerna Pharmaceuticals (NASDAQ:DRNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 29.41%
Institutional Ownership Percentage: 75.28%
Insider Trading History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2018James B WeissmanInsiderSell1,035$13.00$13,455.0018,765View SEC Filing  
12/18/2017Bain Capital Life Sciences InvDirectorBuy285,000$7.00$1,995,000.00View SEC Filing  
11/16/2016Dennis LangerDirectorSell23,766$3.52$83,656.3243,595View SEC Filing  
11/15/2016Douglas FambroughCEOBuy33,100$3.71$122,801.00View SEC Filing  
5/12/2016James B WeissmanInsiderBuy5,000$3.29$16,450.0015,100View SEC Filing  
11/25/2014James E FlynnInsiderSell321,965$11.36$3,657,522.40View SEC Filing  
11/7/2014James E FlynnInsiderSell214,164$9.05$1,938,184.20View SEC Filing  
10/15/2014James E FlynnInsiderSell117,778$10.86$1,279,069.08View SEC Filing  
10/14/2014James E FlynnMajor ShareholderSell36,115$11.02$397,987.30View SEC Filing  
10/10/2014James E FlynnMajor ShareholderSell30,214$12.13$366,495.82View SEC Filing  
2/4/2014James E FlynnInsiderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
2/4/2014Stephen J HoffmanDirectorBuy200,000$15.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dicerna Pharmaceuticals (NASDAQ DRNA) News Headlines

Source:
DateHeadline
Dicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.75 MillionDicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.75 Million
www.americanbankingnews.com - April 18 at 4:15 AM
Zacks: Brokerages Expect Dicerna Pharmaceuticals (DRNA) Will Announce Earnings of -$0.30 Per ShareZacks: Brokerages Expect Dicerna Pharmaceuticals (DRNA) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 16 at 9:25 AM
ValuEngine Lowers Dicerna Pharmaceuticals (DRNA) to SellValuEngine Lowers Dicerna Pharmaceuticals (DRNA) to Sell
www.americanbankingnews.com - April 14 at 2:31 PM
Dicerna Pharmaceuticals (DRNA) Raised to "Buy" at ValuEngineDicerna Pharmaceuticals (DRNA) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - April 12 at 11:18 AM
Dicerna Pharmaceuticals (DRNA) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowDicerna Pharmaceuticals (DRNA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:03 PM
Dicerna to Present at the HC Wainwright Global Life Sciences ConferenceDicerna to Present at the HC Wainwright Global Life Sciences Conference
www.businesswire.com - April 3 at 8:56 AM
Dicerna to Present at the H.C. Wainwright Global Life Sciences ConferenceDicerna to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 3 at 8:56 AM
Dicerna Pharmaceuticals (DRNA) Upgraded by ValuEngine to "Hold"Dicerna Pharmaceuticals (DRNA) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 1 at 10:20 PM
 Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $1.75 Million Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $1.75 Million
www.americanbankingnews.com - April 1 at 4:04 AM
Dicerna Pharmaceuticals (DRNA) Lifted to Hold at ValuEngineDicerna Pharmaceuticals (DRNA) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
Dicerna Pharmaceuticals (DRNA) Lowered to "Hold" at BidaskClubDicerna Pharmaceuticals (DRNA) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 9:27 AM
Equities Analysts Issue Forecasts for Dicerna Pharmaceuticals Incs FY2018 Earnings (DRNA)Equities Analysts Issue Forecasts for Dicerna Pharmaceuticals Inc's FY2018 Earnings (DRNA)
www.americanbankingnews.com - March 30 at 7:05 AM
Dicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Hold" from AnalystsDicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 5:56 PM
Dicerna Pharmaceuticals (DRNA) Coverage Initiated by Analysts at Evercore ISIDicerna Pharmaceuticals (DRNA) Coverage Initiated by Analysts at Evercore ISI
www.americanbankingnews.com - March 28 at 2:06 PM
Dicerna Pharmaceuticals (DRNA) Downgraded by BidaskClub to HoldDicerna Pharmaceuticals (DRNA) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - March 28 at 11:26 AM
B. Riley Initiates Coverage on Dicerna Pharmaceuticals (DRNA)B. Riley Initiates Coverage on Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - March 28 at 8:06 AM
Dicerna Pharmaceuticals (DRNA) Stock Rating Upgraded by ValuEngineDicerna Pharmaceuticals (DRNA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM
Dicerna Pharmaceuticals (DRNA) Lifted to "Strong-Buy" at BidaskClubDicerna Pharmaceuticals (DRNA) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 24 at 8:23 PM
H.C. Wainwright Downgrades Dicerna Pharmaceuticals (DRNA) to Neutral Citing ValuationH.C. Wainwright Downgrades Dicerna Pharmaceuticals (DRNA) to Neutral Citing Valuation
www.streetinsider.com - March 24 at 4:55 PM
Dicerna Pharmaceuticals (DRNA) Stock Rating Lowered by BidaskClubDicerna Pharmaceuticals (DRNA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 23 at 11:22 PM
HC Wainwright Lowers Dicerna Pharmaceuticals (DRNA) to NeutralHC Wainwright Lowers Dicerna Pharmaceuticals (DRNA) to Neutral
www.americanbankingnews.com - March 23 at 2:56 PM
Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - March 23 at 8:49 AM
21 Stocks Moving In Thursdays Pre-Market Session - Benzinga21 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - March 22 at 9:01 AM
Dicerna Pharmaceuticals Inc (DRNA) Insider James B. Weissman Sells 1,035 SharesDicerna Pharmaceuticals Inc (DRNA) Insider James B. Weissman Sells 1,035 Shares
www.americanbankingnews.com - March 21 at 10:10 PM
Dicerna Pharmaceuticals Inc (DRNA) Expected to Announce Quarterly Sales of $1.79 MillionDicerna Pharmaceuticals Inc (DRNA) Expected to Announce Quarterly Sales of $1.79 Million
www.americanbankingnews.com - March 15 at 1:39 PM
Dicerna Pharmaceuticals (DRNA) Presents At 38th Annual Cowen and Company Healthcare Conference - SlideshowDicerna Pharmaceuticals (DRNA) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 13 at 6:54 PM
Dicerna Pharmaceuticals (DRNA) Price Target Increased to $17.00 by Analysts at Stifel NicolausDicerna Pharmaceuticals (DRNA) Price Target Increased to $17.00 by Analysts at Stifel Nicolaus
www.americanbankingnews.com - March 9 at 8:42 PM
Dicerna Pharmaceuticals (DRNA) Receives New Coverage from Analysts at Chardan CapitalDicerna Pharmaceuticals (DRNA) Receives New Coverage from Analysts at Chardan Capital
www.americanbankingnews.com - March 9 at 9:18 AM
Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium - Business Wire (press release)Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium - Business Wire (press release)
www.businesswire.com - March 9 at 9:04 AM
Dicerna Pharmaceuticals (DRNA) CEO Douglas Fambrough on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaDicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 9:04 AM
Dicerna Pharmaceuticals (DRNA) Releases Quarterly  Earnings Results, Misses Expectations By $0.25 EPSDicerna Pharmaceuticals (DRNA) Releases Quarterly Earnings Results, Misses Expectations By $0.25 EPS
www.americanbankingnews.com - March 8 at 9:13 PM
Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate UpdateDicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - March 8 at 6:06 PM
Dicerna to Present at the Cowen and Company 38th Annual Health Care ConferenceDicerna to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 8:47 AM
Dicerna Pharmaceuticals Inc (DRNA) Receives Average Recommendation of "Buy" from AnalystsDicerna Pharmaceuticals Inc (DRNA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 3 at 5:56 PM
Dicerna Pharmaceuticals (DRNA) Set to Announce Quarterly Earnings on ThursdayDicerna Pharmaceuticals (DRNA) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 2 at 8:10 PM
Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018
finance.yahoo.com - March 1 at 8:39 AM
Zacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $4.43 MillionZacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $4.43 Million
www.americanbankingnews.com - February 26 at 10:48 AM
 Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) to Post -$0.56 EPS Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) to Post -$0.56 EPS
www.americanbankingnews.com - February 24 at 9:26 AM
BidaskClub Upgrades Dicerna Pharmaceuticals (DRNA) to BuyBidaskClub Upgrades Dicerna Pharmaceuticals (DRNA) to Buy
www.americanbankingnews.com - February 21 at 10:34 PM
VYGR Soars On Alzheimers Deal, RARX Up 21% In 5 Days, ATXI Catches EyesVYGR Soars On Alzheimer's Deal, RARX Up 21% In 5 Days, ATXI Catches Eyes
www.nasdaq.com - February 21 at 8:49 AM
Dicerna Pharmaceuticals Inc (DRNA) Short Interest UpdateDicerna Pharmaceuticals Inc (DRNA) Short Interest Update
www.americanbankingnews.com - February 11 at 1:52 AM
Dicerna Pharmaceuticals (DRNA) Rating Lowered to Sell at Zacks Investment ResearchDicerna Pharmaceuticals (DRNA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 10:04 PM
Zacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Announce Quarterly Sales of $4.43 MillionZacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Announce Quarterly Sales of $4.43 Million
www.americanbankingnews.com - February 9 at 4:12 AM
 Analysts Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Earnings of -$0.61 Per Share Analysts Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - February 7 at 9:52 AM
Brokers Issue Forecasts for Dicerna Pharmaceuticals Incs FY2017 Earnings (DRNA)Brokers Issue Forecasts for Dicerna Pharmaceuticals Inc's FY2017 Earnings (DRNA)
www.americanbankingnews.com - February 7 at 9:22 AM
Dicerna Pharmaceuticals Inc (DRNA) Given Average Rating of "Hold" by BrokeragesDicerna Pharmaceuticals Inc (DRNA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 6 at 5:42 PM
SunTrust Banks Begins Coverage on Dicerna Pharmaceuticals (DRNA)SunTrust Banks Begins Coverage on Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - February 5 at 8:42 PM
Dicerna Pharmaceuticals (DRNA) Downgraded by Zacks Investment ResearchDicerna Pharmaceuticals (DRNA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 1 at 9:48 PM
BidaskClub Lowers Dicerna Pharmaceuticals (DRNA) to HoldBidaskClub Lowers Dicerna Pharmaceuticals (DRNA) to Hold
www.americanbankingnews.com - January 31 at 11:58 PM
Dicerna Pharmaceuticals (DRNA) Upgraded by BidaskClub to "Buy"Dicerna Pharmaceuticals (DRNA) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 28 at 9:30 AM

SEC Filings

Dicerna Pharmaceuticals (NASDAQ:DRNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dicerna Pharmaceuticals (NASDAQ:DRNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dicerna Pharmaceuticals (NASDAQ DRNA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.